Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQJXL4)

Drug Name
AMG 386 Drug Info
Synonyms
7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [1] , [2]
Neuropathic pain 8E43.0 Phase 3 [3]
Alzheimer disease 8A20 Phase 2 [4]
Asthma CA23 Discontinued in Phase 2 [5]
Sexual dysfunction HA00-HA01 Preclinical [6]
Cross-matching ID
PubChem CID
5360545
ChEBI ID
CHEBI:26708
CAS Number
CAS 7440-23-5
TTD Drug ID
DMQJXL4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Angiopoietin-2 (ANGPT2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Faricimab DM83SEB Diabetic macular edema 9B71.02 Phase 3 [10]
Trebananib DMOG2X1 Ovarian cancer 2C73 Phase 3 [11]
RG7221 DM8J9DC Colorectal cancer 2B91.Z Phase 2 [12]
RO5520985 DMD3WNP Colorectal cancer 2B91.Z Phase 2 [13]
REGN910-3 DMTBRPO Neovascular age-related macular degeneration 9B78.3Z Phase 2 [14]
CVX-060 DM03LWZ Solid tumour/cancer 2A00-2F9Z Phase 1/2 [15]
BI 836880 DMRI6YT Neoplasm 2A00-2F9Z Phase 1 [16]
CVX-241 DMV74JC Solid tumour/cancer 2A00-2F9Z Phase 1 [17]
LY3127804 DM5OP86 Solid tumour/cancer 2A00-2F9Z Phase 1 [18]
REGN-910 DMHR7D4 Solid tumour/cancer 2A00-2F9Z Phase 1 [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Opioid receptor (OPR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methadone DMTW6IU Dry cough MD12 Approved [20]
Ketobemidone DMM3L6Z Pain MG30-MG3Z Approved [21]
Oxymorphone DM65AGJ Pain MG30-MG3Z Approved [22]
Dextropropoxyphene DM23HCX Pain MG30-MG3Z Approved [23]
Sufentanil DMU7YEL Analgesia MB40.8 Approved [24]
Naltrexone DMUL45H Alcohol dependence 6C40.2 Approved [25]
Levorphanol DMGS80V Pain MG30-MG3Z Approved [26]
Pentazocine DM1XBHS Pain MG30-MG3Z Approved [27]
Nalmefene DM4YWCZ Opioid dependence 6C43.2Z Approved [28]
Tilidine DMJW0VS Pain MG30-MG3Z Approved [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Neuronal acetylcholine receptor alpha-7 (CHRNA7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ziprasidone DMM58JY Schizophrenia 6A20 Approved [30]
ALCURONIUM DM2U4XQ Anaesthesia 9A78.6 Approved [31]
CYTISINE DMUF0BJ Tobacco dependence 6C4A.2 Phase 3 [32]
EVP-6124 DMLQO7F Alzheimer disease 8A20 Phase 3 [33]
GTS-21 DMEN5KA Parkinson disease 8A00.0 Phase 2 [34]
JNJ-39393406 DMUOEKM Depression 6A70-6A7Z Phase 2 [35]
ABT-126 DM2OS51 Alzheimer disease 8A20 Phase 2 [36]
TC-6987 DMNFP21 Asthma CA23 Phase 2 [37]
AQW-051 DMD2RFO Alzheimer disease 8A20 Phase 2 [38]
MEM-3454 DMPNDYU Schizophrenia 6A20 Phase 2 [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Angiopoietin-1 (ANGPT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trebananib DMOG2X1 Ovarian cancer 2C73 Phase 3 [11]
AMG 780 DMTGZN8 Solid tumour/cancer 2A00-2F9Z Phase 1 [39]
Drug(s) Targeting TAX transcriptionally-activated glycoprotein 1 (OX40)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RG7888 DM2SWI8 Solid tumour/cancer 2A00-2F9Z Phase 2 [40]
mRNA-2752 DMUKBI2 Solid tumour/cancer 2A00-2F9Z Phase 1 [41]
MEDI6383 DM1YSMD Solid tumour/cancer 2A00-2F9Z Phase 1 [42]
mRNA-2416 DMFTAWU Lymphoma 2A80-2A86 Phase 1 [43]
Drug(s) Targeting Melanocortin receptor 4 (MC4R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methylnaltrexone bromide DMZTGN2 Opioid-induced constipation DB32.1 Approved [6]
Bremelanotide DM20LIM Hypoactive sexual desire dysfunction HA00 Approved [44]
Setmelanotide DMPVRN9 Obesity 5B81 Approved [45]
Amylin DMWDEN0 N. A. N. A. Phase 4 [46]
PMX-53 DMZUAJ4 Atopic dermatitis EA80 Phase 2 [47]
PF-446687 DML38VU Female sexual arousal dysfunction HA01.1 Phase 2 [48]
AP-1030 DMBGA35 Metabolic disorder 5C50-5D2Z Phase 1/2 [7]
PT-14 DMYM9JL Erectile dysfunction HA01.1 Discontinued in Phase 2 [49]
Melanotetan II DMYK8MV Obesity 5B81 Preclinical [6]
IDDBCP-150101 DMQ3BXV Obesity 5B81 Preclinical [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Gamma-secretase (GS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [50]
Semagacestat DML83IW Parkinson disease 8A00.0 Phase 3 [51]
PF-03084014 DMUP5Z0 Desmoid tumour 2F7C Phase 3 [52]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [50]
MK-0752 DMLTAES Alzheimer disease 8A20 Phase 2 [53]
BMS-708163 DM51LTG Alzheimer disease 8A20 Phase 2 [54]
CHF-5074 DMTE071 Alzheimer disease 8A20 Phase 2 [55]
RO-4929097 DMXA6B3 Breast cancer 2C60-2C65 Phase 2 [56]
AL102 DMCTWIB Desmoid tumour 2F7C Phase 2 [57]
SPI-014 DM5IPUS Alzheimer disease 8A20 Phase 1 [58]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin-1 (ANGPT1) TTWNQ1T ANGP1_HUMAN Modulator [7]
Angiopoietin-2 (ANGPT2) TTKLQTJ ANGP2_HUMAN Modulator [7]
Gamma-secretase (GS) TT9W8GU APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN Inhibitor [8]
Melanocortin receptor 4 (MC4R) TTD0CIQ MC4R_HUMAN Agonist [6]
Neuronal acetylcholine receptor alpha-7 (CHRNA7) TTLA931 ACHA7_HUMAN Agonist [8]
Opioid receptor (OPR) TTN4QDT NOUNIPROTAC Agonist [3]
TAX transcriptionally-activated glycoprotein 1 (OX40) TTBW580 TNFL4_HUMAN Modulator [9]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8414).
2 ClinicalTrials.gov (NCT01281254) TRINOVA-2: Trebananib in Ovarian Cancer-2. U.S. National Institutes of Health.
3 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
4 Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov. 2009 Sep;8(9):733-50.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027884)
6 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8 Clinical pipeline report, company report or official report of Roche (2009).
9 Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68.
10 Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
11 Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
12 Company report (Roche pipeline: July 27, 2017)
13 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
14 ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
15 Clinical pipeline report, company report or official report of CovX (2011).
16 Clinical pipeline report, company report or official report of Boehringer Ingelheim.
17 Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19 Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18.
20 Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
21 The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
23 Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
24 mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
25 An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
26 Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22.
27 Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
28 Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97.
29 Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8.
30 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
31 Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29.
32 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97.
33 Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24.
34 The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81.
35 Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204.
36 A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90.
37 ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
38 AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23.
39 Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Cancer Research. 10/2014; 74(19 Supplement):1022-1022.
40 Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105.
41 Clinical pipeline report, company report or official report of Moderna Therapeutics.
42 J Clin Oncol 33, 2015 (suppl; abstr 3056).
43 Clinical pipeline report, company report or official report of Moderna Therapeutics.
44 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
45 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
46 Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
47 Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
48 Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65.
49 The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51.
50 The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
51 A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50.
52 Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.J Pharmacol Exp Ther.2010 Jul;334(1):269-77.
53 Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52.
54 Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69(11):1430-40.
55 CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.Br J Pharmacol.2009 Mar;156(6):982-93.
56 Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53.
57 Clinical pipeline report, company report or official report of Ayala Pharmaceuticals.
58 Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:210756.